Navigation Links
Stem Cells Show Promise in Extending Transplanted Kidneys’ Survival Time
Date:2/7/2013

Durham, NC (PRWEB) February 07, 2013

Kidney transplants have long been the treatment of choice for many patients with end-stage renal disease, and the short-term results are excellent. But unfortunately, the viability of these kidneys over time has not improved accordingly, often due to fibrosis, which is a scarring of the transplanted organ generally caused by the immune system rejecting it.

The LUMC team, led by Marlies E.J. Reinders, M.D, Ph.D., and Ton J. Rabelink, M.D., Ph.D., decided to test whether stem cells might keep fibrosis in check. They focused on mesenchymal stromal cells, a type of stem cell found throughout the body, including in bone marrow.

“Mesenchymal stromal cells (MSCs) are an interesting candidate due to their immunosuppressive and regenerative properties,” Dr. Reinders explained. “Of importance, no clinical studies have investigated their effects on rejection and fibrosis in organ transplantation.”

The team performed a safety and feasibility study in kidney transplant patients who, at four weeks or six months after transplant, were showing signs of rejection and/or an increase in fibrosis and wasting away of the kidney’s tubes (a condition called interstitial fibrosis/tubular atrophy. . In all, six patients received two intravenous MSC infusions of 1 million cells, collected from the patient’s own bone marrow and given one week apart. None of the patients had any sign of adverse, treatment-related side effects from the MSCs, although three developed infections associated with immune suppression.

Five of the patients had a specific decrease in immunity against the transplanted organ. In agreement, prior to the infusions, two of the patients had tubulitis — lesions that are a warning sign of organ rejection — which disappeared after the MSC treatment.

“These first clinical observations support the potential of stem cells as a novel cell therapy to prevent allograft rejection and interstitial fibrosis/tubular atrophy,” Dr. Rabelink noted, adding that long-term follow-up to better understand MSC-based treatment and to monitor unwanted side effects is needed, especially since transplant recipients are already at an increased risk for infection and malignancies.

“While the study wasn’t designed to test efficacy, these clinical observations are promising and suggestive of systemic immunosuppression,” said Anthony Atala, M.D., Editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

###

The full article, “Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study,” can be accessed at http://stemcellstm.alphamedpress.org/content/early/2013/01/23/sctm.2012-0114.abstract.

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), celebrating its 31th anniversary in 2012, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10404531.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. NSG Precision Cells Now Offering a High Grade Flow Through Cell with Unparalled Quality
2. 3D printing breakthrough with human embryonic stem cells
3. A gut feeling about neural stem cells
4. 1 in, 2 out: Simulating more efficient solar cells
5. Cornell bioengineers discover the natural switch that controls spread of breast cancer cells
6. NSG Precision Cells’ WAV-7 Didymium Standard Makes Calibrating Wavelength Accuracy a Snap
7. Living cells behave like fluid-filled sponges
8. Mesenchymal Stem Cells Mobilize Body’s Own Healing Cells According to New Research Published in STEM CELLS Translational Medicine
9. Autoimmune disease retraining white blood cells
10. Breast cancer cells growing in 3D-matrix revert to normal
11. The birth of new cardiac cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
Breaking Biology News(10 mins):